


In the claims:

1. (Currently Amended) A method for treating inflammatory disease, ~~mediated by~~ comprising inhibiting monocyte chemoattractant protein-1 and/or RANTES-induced chemotaxis, said method comprising administering to a patient in need thereof an effective amount of a compound of formula (I)




(I)

or a pharmaceutically acceptable salt, amide or ester thereof; wherein

X is CH<sub>2</sub> or SO<sub>2</sub>;

R<sup>1</sup> is an optionally substituted aryl ring;

R<sup>2</sup> is carboxy, cyano, -C(O)CH<sub>2</sub>OH, -CONHR<sup>8</sup>, -SO<sub>2</sub>NHR<sup>9</sup>, tetrazol-5-yl, SO<sub>3</sub>H, or a group of formula (VI)



(VI)

where R<sup>8</sup> is selected from hydrogen, alkyl, aryl, cyano, hydroxy, -SO<sub>2</sub>R<sup>12</sup> where R<sup>12</sup> is alkyl, aryl, or haloalkyl, or R<sup>8</sup> is a group-(CHR<sup>13</sup>)<sub>r</sub>-COOH where r is an integer of 1-3 and each R<sup>13</sup> group is independently selected from hydrogen or alkyl; R<sup>9</sup> is hydrogen, alkyl, or optionally substituted aryl, or a group COR<sup>14</sup> where R<sup>14</sup> is alkyl, aryl, or haloalkyl; and R<sup>10</sup> and R<sup>11</sup> are independently selected from hydrogen or alkyl, particularly C<sub>1-4</sub> alkyl;

$R^3$  is a group  $OR^{15}$ ,  $S(O)_qR^{15}$ ,  $NHCOR^{16}$ ,  $NHSO_2R^{16}$ ,  $(CH_2)_sCOOH$ ,  $(CH_2)_tCONR^{17}R^{18}$ ,  $NR^{17}R^{18}$ ,  $SO_2NR^{17}R^{18}$  or optionally substituted alkenyl, where  $q$  is 0, 1 or 2,  $s$  is 0 or an integer of from 1 to 4,  $t$  is 0 or an integer of from 1 to 4,  $R^{15}$  is a substituted alkyl or cycloalkyl group,  $R^{16}$  is optionally substituted alkyl or optionally substituted aryl, and  $R^{17}$  and  $R^{18}$  are independently selected from hydrogen, optionally substituted alkyl, and optionally substituted aryl, with the proviso that at least one of  $R^{17}$  or  $R^{18}$  is other than hydrogen; and

$R^4$  is selected from hydrogen, hydroxyl, halo, alkoxy, aryloxy, araalkyl, carboxyalkyl, or an amide derivative thereof ~~for an optionally substituted hydrocarbyl group, provided that  $R^4$  is other than an alkyl group substituted by  $OR^{18}$ ,  $S(O)_mR^{18}$ , or  $NR^{19}R^{20}$ , where  $R^{18}$ ,  $R^{19}$  and  $R^{20}$  are independently selected from hydrogen or optionally substituted hydrocarbyl, or  $R^{19}$  and  $R^{20}$  together with the atom to which they are attached, form an optionally substituted heterocyclyl ring as defined above which optionally contains further heteroatoms, and  $m$  is 0 or an integer of from 1 to 3; and~~

$R^5$ ,  $R^6$ , and  $R^7$  are independently selected from hydrogen, hydroxyl, halo, alkoxy, or an optionally substituted hydrocarbyl group.

2. (Cancelled)

3. (Previously Presented) A method according to claim 1, wherein  $R^3$  is  $OR^{15}$ ,  $S(O)_qR^{15}$ ,  $NHCOR^{16}$ ,  $NHSO_2R^{16}$ , or  $SO_2NR^{17}R^{18}$ , where  $q$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$  and  $R^{18}$  are as defined in claim 1.

4. (Previously Presented) A method according to claim 1, wherein  $R^3$  is a group of formula - $O(CH_2)_a[(CHOH)(CH_2)_b]_dCH_2OH$ , where  $a$  is 0 or an integer of from 1 to 4,  $b$  is 0 or an integer of from 1 to 3, and  $d$  is 0 or 1.

5. (Previously Presented) A method according to claim 1, wherein  $R^1$  is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl, or 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl.

6. (Previously Presented) A method according to claim 1, wherein  $X$  is  $CH_2$ .

7. (Cancelled)

8. (Previously Presented) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 subject to the following provisos:


- (i) when  $R^2$  is carboxy or a salt or amide thereof, at least three of  $R^4$ ,  $R^5$ ,  $R^6$ , and  $R^7$  are hydrogen, and  $R^3$  is  $S(O)_qR^{15}$ , then  $R^{15}$  is other than  $C_{1-4}$  alkyl substituted by carboxy or an ester or amide derivative thereof;
- (ii) when  $R^3$  is a group  $NHCOR^{16}$ , then  $R^{16}$  is optionally substituted alkyl; and
- (iii) when  $R^3$  is a group  $SR^{15}$ , where  $R^{15}$  is 2-quinolylmethyl,  $R^2$  is COOH or an ethyl ester thereof, each of  $R^4$ ,  $R^5$ , and  $R^7$  are hydrogen, and  $R^1$  is 4-chlorophenyl, then  $R^6$  is other than 2-quinolylmethyl;

in combination with a pharmaceutically acceptable carrier.

9. (Previously Presented) A compound of formula (I) as defined in claim 1, subject to the following provisos:


- (i) when  $R^2$  is carboxy or a salt or amide thereof, at least three of  $R^4$ ,  $R^5$ ,  $R^6$ , and  $R^7$  are hydrogen, and  $R^3$  is  $S(O)_qR^{15}$ , then  $R^{15}$  is other than  $C_{1-4}$  alkyl substituted by carboxy or an ester or amide derivative thereof;
- (ii) when  $R^3$  is a group  $NHCOR^{16}$ , then  $R^{16}$  is optionally substituted alkyl; and
- (iii) when  $R^3$  is a group  $SR^{15}$ , where  $R^{15}$  is 2-quinolylmethyl,  $R^2$  is COOH or an ethyl ester thereof, each of  $R^4$ ,  $R^5$ , and  $R^7$  are hydrogen, and  $R^1$  is 4-chlorophenyl, then  $R^6$  is other than 2-quinolylmethyl;
- (iv) when  $R^3$  is a group COOH or  $CH_2COOH$ ,  $R^2$  is COOH and each of  $R^4$ ,  $R^5$ ,  $R^6$  and  $R^7$  are hydrogen, then  $R^1$  is other than unsubstituted phenyl;
- (v) when  $R^3$  is a group  $CH_2COOH$ ,  $R^2$  is COOH and each of  $R^4$ ,  $R^5$ , and  $R^7$  are hydrogen,  $R^1$  is 4-chlorophenyl, then  $R^6$  is other than methoxy;
- (vi) when  $R^3$  is  $OR^{15}$  or  $S(O)_qR^{15}$ , then  $R^{15}$  is other than  $C_{1-6}$  haloalkyl; and
- (vii) when  $R^2$  is  $COOCH_2CH_3$ , each of  $R^4$ ,  $R^5$ ,  $R^6$  and  $R^7$  are hydrogen, and  $R^1$  is 4-chlorophenyl, then  $R^3$  is other than a group  $CH=CH(CN)_2$ .

10. (Currently Amended) A method of preparing a compound of formula (I) as defined in claim 1, which method comprises reacting a compound of formula (VII)



(VII)

where R4, R5, R6 and R7 are as defined in claim 1, R2' is a group R2 as defined in claim 1 or a protected form thereof, and R3' is a group R3 as defined in claim 1 ~~or a group which can be converted to a group R3~~; with a compound of formula (VIII)



(VIII)

where R1 and X are as defined in claim 1 and Z1 is a leaving group; and thereafter optionally ~~carrying out one or more of the following steps:~~

- ~~(i) — changing a group R3' which is other than a group R3 to a group R3 or where R3' is a group R3, changing this to a different such group;~~
- ~~(ii) — removing any protecting group from R2'.~~